Document:

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT 

 

THE
CHRON ORGANIZATION, INC. 

 

	   Warrant
    No. A-01	Issue
    Date: March 17, 2017

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Bellridge Capital,
LLC (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the six month anniversary of the date hereof (the “Initial Exercise
Date”) and on or prior to the close of business on the three anniversary of the issue date of this Warrant (the
“Termination Date”) but not thereafter, to subscribe for and purchase from The ChronOrganization, Inc.,
a Nevada corporation (the “Company”), up to 500,000 shares (the “Warrant Shares”)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).

 

Section
1. Definitions. For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized
terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall
have the following meanings:

 

“Business
Day” means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United
States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental
action to close.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof
to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
receive Common Stock.

 

“Fair
Market Value” of one share of Common Stock as of a particular date shall mean: (i) if traded on a National Securities
Exchange, the VWAP (as defined below) of the Common Stock of the Company on such exchange over the five (5) Trading Days ending
immediately prior to the applicable date of valuation; (ii) if quoted on the OTCQB or the OTCPink or its successor, the average
VWAP over the thirty (30) Trading Days ending immediately prior to the applicable date of valuation; and (iii) if neither (i)
nor (ii) applies, the Fair Market Value shall be the value thereof, as agreed upon by the Company and the Holder; provided, however,
that if the Company and the Holder cannot agree on such value, such value shall be determined by an independent valuation firm
experienced in valuing businesses such as the Company and jointly selected in good faith by the Company and the Holder. Fees and
expenses of the valuation firm shall be paid for by the Company.

 

    	 	1

     

    

 

'“National
Securities Exchange” means the following markets or exchanges on which the Common Stock may be listed or quoted
for trading on the date in question: the NYSE MKT, LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global
Select Market, the New York Stock Exchange.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Purchase
Agreement” means, collectively, the Securities Purchase Agreement, dated as of March 15, 2017, between the Company
and the original Holder, as amended, modified or supplemented from time to time in accordance with its terms.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the New York Stock Exchange is open for business.

 

“Trading
Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the NYSE AMEX LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, the OTCQB or the OTCPink.

 

“Transaction
Documents” shall have the meaning set forth in the Purchase Agreement.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a National Securities Exchange, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the trading market on which the Common Stock is then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. New York City time to 4:02 p.m. New York City time); (b) if the Common Stock is quoted
on any one or more of the OTC Bulletin Board, or the other OTC markets, including the OTCQX, OTCQB and OTCPink, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTC Markets, including the OTCQX, OTCQB and
the OTCPink; or (cd) in all other cases, the Fair Market Value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Subscribers of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company; provided that in each case where Bloomberg L.P. data
is being relied upon, Holder shall provide to the Company a copy of such information for the Company’s records.

 

    	 	2

     

    

 

	Section
    2.	Exercise

 

a)
Exercise of Warrant. 

 

i.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed notice of exercise (“Notice of Exercise”) form attached hereto as
Exhibit A; and, within three (3) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company
shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s
check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. In the event
of any dispute or discrepancy, the records of the Company shall be controlling and determinative in the absence of manifest error.

 

ii.
If at any time after six (6) months from the Initial Exercise Date, in lieu of the payment methods set forth in Section 2(a)(i)
above, the Holder may elect to exchange all or some of this Warrant for shares of Common Stock equal to the value of the amount
of the Warrant being exchanged on the date of exchange. If Holder elects to exchange this Warrant as provided in this Section
2(a)(ii), Holder shall tender to the Company the Warrant for the amount being exchanged, along with written notice of Holder’s
election to exchange some or all of the Warrant, and the Company shall issue to Holder the number of shares of the Common Stock
computed using the following formula:

 

	X
    =	Y
    (A-B)
	 	A

 

	 	Where:	X
    =	the
                                         number of shares of Common Stock to be issued to Holder.

        

	 	 	 	 
	 	 	Y
    =	the
    number of shares of Common Stock purchasable under the amount of the Warrant being exchanged (as adjusted to the date of such
    calculation).
	 	 	 	 
	 	 	A
    =	the
    Fair Market Value of one share of the Common Stock on the date that the notice of exercise is received by the Company.
	 	 	 	 
	 	 	B
    =	Exercise
    Price (as adjusted to the date of such calculation).

 

b)       Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $.03 [SECOND WARRANT EXERCISE PRICE IS
$.05], subject to adjustment hereunder (the “Exercise Price”).

 

    	 	3

     

    

 

c)       Exercise
Limitations. Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise,
to the extent that after giving effect to such issuance after exercise, the Holder (together with the Holder’s affiliates,
and any other person or entity acting as a group together with the Holder or any of the Holder’s affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of this Section, beneficial ownership shall
be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Holder
is solely responsible for any schedules required to be filed in accordance therewith. The Company shall have no obligation to
verify or confirm the accuracy of such filings. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership
Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of Warrant Shares issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(c), provided
that the Beneficial Ownership Limitation may not exceed 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this
Section 2(c) shall continue to apply, unless the Holder upon not less than 61 days’ prior notice to the Company determines
to waive the Beneficial Ownerhship Limitation requirements described in this Section 2(c) in its entirety. Any such increase or
decrease will not be effective until the 61st day after such notice is delivered to the Company. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.

 

d)       Mechanics
of Exercise.

 

i.       Delivery
of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Company’s transfer
agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s prime broker
with the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if
the Company is then a participant in such system and either (A) there is an effective registration statement permitting the resale
of the Warrant Shares by the Holder or (B) the shares are eligible for resale without volume or manner-of-sale limitations pursuant
to Rule 144, and otherwise by physical delivery of certificates to the address specified by the Holder in the Notice of Exercise
within four (4) Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant (if required)
and payment of the aggregate Exercise Price as set forth above (the “Warrant Share Delivery Date”).
This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company. The Warrant Shares
shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have
become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company
of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(e)(vi) prior to the issuance
of such shares, have been paid.

 

ii.       Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for
by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

    	 	4

     

    

 

iii.       Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing
the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind
such exercise.

 

iv.       No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

v.       Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the assignment form (“Assignment
Form”) attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. Without limiting the generality of the
forgoing the Holder may assign all or part of this Warrant and the Company agrees to honor such assignment.

 

vi.       Closing
of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

Section
3. Subsequent Equity Sales. Other than in connectioni with an Exepmpt Issuance, if the Company or any Subsidiary thereof,
as applicable, at any time while this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any
right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition)
any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock, at an effective price per
share less than the then Exercise Price (such lower price, the “Base Share Price” and such issuances collectively,
a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any
time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or
otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive
shares of Common Stock at an effective price per share which is less than the Exercise Price, such issuance shall be deemed to
have occurred for less than the Exercise Price on such date of the Dilutive Issuance), then, the Exercise Price shall be reduced
and only reduced to equal the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that
the aggregate Exercise Price payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to
the aggregate Exercise Price prior to such adjustment. Such adjustment shall be made whenever such Common Stock or Common Stock
Equivalents are issued. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section in respect
of an Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day following the issuance of
any Common Stock or Common Stock Equivalents subject to this Section indicating therein the applicable issuance price, or applicable
reset price, exchange price, conversion price and other pricing terms (such notice, the “Dilutive Issuance Notice”).
For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section, upon the
occurrence of any Dilutive Issuance, after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant
Shares based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice
of Exercise. For avoidance of doubt in the event of an issuance of securities (including convertible promissory notes, debentures,
warrants or like securities), involving multiple tranches or other multiple closings the anti-dilution adjustment shall be calculated
as if all of the securities were issued at the first closing for such sale.

 

    	 	5

     

    

 

Section
4. Certain Adjustments.

 

a)       Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 4(a) shall become
effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)
       Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding,
shall distribute to all holders of Common Stock (and not to the Holder) evidences of its indebtedness or assets (including cash
and cash dividends) or rights or warrants to subscribe for or purchase any security other than the Common Stock, then in each
such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date
fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be
the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less
than the per share Fair Market Value at such record date of the portion of such assets or evidence of indebtedness or rights or
warrants so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors in good
faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences
of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made
whenever any such distribution is made and shall become effective immediately after the record date mentioned above.

 

    	 	6

     

    

 

 

c)       Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company effects any merger or consolidation of the
Company into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of
related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property or (iv)
the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock
is effectively converted into or exchanged for other securities, cash or property (each “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity
in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate Consideration. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions
of this Section 4(c) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent
transaction analogous to a Fundamental Transaction.

 

d)
Calculations. All calculations under this Section 4 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 4, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

e)       Notice
to Holder.

 

i.       Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 4, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.

 

ii.       Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing
thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder is entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice.

 

    	 	7

     

    

 

Section
5. Transfer of Warrant.

 

a)       Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 5(d) herein and to the provisions
of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant
issued.

 

b)       New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 5(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial
Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)       Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

    	 	8

     

    

 

 

d)       Transfer
Restrictions. If, at the time
of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either
(i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible
for resale without volume or manner-of-sale restrictions pursuant to Rule 144, the Company may require, as a condition of allowing
such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of the Purchase Agreement.

 

Section
6. Miscellaneous.

 

a)       No
Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder
of the Company prior to the exercise hereof.

 

b)       Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)       Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

d)       Authorized
Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock one hundred (100%) of the number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. In case such amount of Common Stock is insufficient at any time, the Company shall call and hold a
special meeting to increase the number of authorized shares of common stock. Management of the Company shall recommend to shareholders
to vote in favor of increasing the number of authorized shares of common stock.

 

The
Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise
of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the National Securities Exchange upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and
charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

    	 	9

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its amended and restated certificate of incorporation, as amended, or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value
of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)
take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)       Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.

 

f)       Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.

 

g)       Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision
of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.

 

h)       Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

i)       Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

    	 	10

     

    

 

j)       Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

k)       Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by
the Holder or holder of Warrant Shares.

 

l)       Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m)       Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n)       Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

[Signature
Page Follows.] 

 

    	 	11

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	the
    chron organization, inc.	 
	 	                              	 
	By:	/s/
    Alex Rodriguez	 
	Name:	Alex
    Rodriguez	 
	Title:	CEO	 

 

    	 

     

    

 

EXHIBIT
A

 

NOTICE
OF EXERCISE

 

TO:
The Chron Organization, Inc.

 

(1)       The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)       Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

 

_______________________________       

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(3)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

	Name
    of Investing Entity:	 
	 	 
	 	 
	Signature
    of Authorized Signatory of Investing Entity:	 
	 	 
	 	 
	Name
    of Authorized Signatory:	 
	 	 
	 	 
	Title
    of Authorized Signatory:	 
	 	 
	 	 
	Date:	 
	 	 

 

    	 

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

_______________________________________________
whose address is

 

____________________________________________________________.

 

_______________________________________________________________

 

Dated:
______________, _______

 

Holder’s
Signature: ____________________________

 

Holder’s
Address: ____________________________

 

_____________________________

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.FORM
OF

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of _______ ___, 2016, is entered into by and between The
Chron Organization, Inc. (OTCPk: CHRO), a Nevada corporation, (“Chron” or the “Company”), and ________________
(the “Buyer”).

 

A.
The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “1933 Act”).

 

B.
Upon the terms and conditions stated in this Agreement, the Buyer desires to purchase and the Company desires to issue and sell,
upon the terms and conditions set forth in this Agreement (i) a Convertible Note, in the form attached hereto as Exhibit
A, in the principal amount of up to $____________ (the “Note”), convertible into shares of common stock,
$0.001 par value per shares of common stock of the Company (“Common Stock”) (ii) and a two-year share purchase
warrant entitling the Buyer to acquire shares of Common Stock in the form attached hereto as Exhibit B (the “Warrant”).

 

NOW
THEREFORE, the Company and the Buyer hereby agree as follows:

 

1.
Purchase and Sale. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer
agrees to purchase from the Company (i) the Note and (ii) the Warrant.

 

1.1.
Form of Payment. On the Closing Date, (i) the Buyer shall pay the purchase price of $___________ (the “Purchase
Price”) for the Note and Warrant by wire transfer of immediately available funds to an account designated by the Company,
in accordance with the Company’s written wiring instructions and (ii) the Company shall deliver the Note and Warrant to
the Buyer.

 

1.2.
Closing Date. The date and time of the issuance and sale of the Note, Warrant and Security Agreement pursuant to this Agreement
(the “Closing Date”) shall be on or about _______, 2016, or such other mutually agreed upon time. The closing
of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such
location as may be agreed to by the parties.

 

2.
Buyer Representations, Warranties, Etc.; Access to Information; Independent Investigation.

 

The
Buyer represents
and warrants
to, and covenants
and agrees
with, the Company
as follows:

 

2.1.
Without limiting
Buyer’s right
to sell the Securities
pursuant to an effective
registration
statement or otherwise
in compliance
with the 1933 Act, the
Buyer is purchasing
the securities
for its own account
for investment only and
not with a view towards the public
sale or distribution
thereof and not with
a view to or for sale
in connection
with any distribution thereof.

 

2.2.
The Buyer is (i) an “accredited
investor” as that term is defined
in Rule 501 of the General
Rules and Regulations
under the 1933 Act by
reason of Rule 501(a)(3),
(ii) experienced
in making investments
of the kind described
in this Agreement and
the other Transaction Documents, (iii) able,
by reason
of the business and financial
experience
of its officers (if an
entity)
and professional
advisors (who are
not affiliated
with or compensated in any
way by the Company
or any of
its Affiliates or selling
agents),
to protect its own interests
in connection with the Transactions
described in this Agreement,
and the related
documents,
and to evaluate
the merits and risks of an
investment
in the Securities,
and (iv) able to afford
the entire loss of its investment
in the Securities.

 

    	 

    	 

    

 

2.3.
The Buyer understands
that the Securities
are being offered
and sold to it in reliance
on specific exemptions
from the registration
requirements of
the 1933 Act and state
securities
laws and that the Company
is relying
upon the truth and accuracy
of, and the Buyer’s
compliance
with, the representations,
warranties,
agreements,
acknowledgments
and understandings
of the Buyer set forth
herein
in order to determine
the availability
of such exemptions
and the eligibility
of the Buyer to acquire
the Securities.

 

2.4.
The Buyer and its
advisors, if any,
have been
furnished with or have been
given access
to all materials
relating to the
business, finances
and operations
of the Company and
materials relating
to the offer
and sale
of the Securities
which have been
requested
by the Buyer,
including those set forth
on any annex
attached
hereto.
The Buyer and its
advisors, if any,
have been
afforded
the opportunity
to ask questions
of the Company and its
management
and have
received
complete
and satisfactory
answers
to any
such inquiries.

 

2.5.
The Buyer understands
that its investment in the Securities
involves a high
degree
of risk.

 

2.6.
The Buyer hereby
represents
that, in connection
with its purchase
of the Securities,
it has not relied
on any statement
or representation
by the Company or any
of its officers,
directors and
employees
or any of their
respective
attorneys
or agents, except
as specifically
set forth herein.

 

2.7.
The Buyer understands
that no United States federal
or state agency
or any
other government
or governmental
agency
has passed
on or made any
recommendation
or endorsement of the Securities.

 

2.8.
This Agreement
and the other Transaction
Documents to which
the Buyer is a party,
and the Transactions
contemplated thereby,
have been duly
and validly
authorized,
executed
and delivered
on behalf
of the Buyer and are
valid and
binding agreements
of the Buyer enforceable
in accordance
with their respective
terms, subject
as to enforceability
to general
principles of equity and
to bankruptcy,
insolvency,
moratorium and
other similar
laws affecting
the enforcement
of creditors’
rights generally.

 

3.
Certain Transactions. The Buyer covenants that neither it, nor any Affiliate acting on its behalf or pursuant to any
understanding with it will execute any short sales as defined in Rule 200 of Regulation SHO under the Exchange Act (“Short
Sales”), of any of the Company’s securities during the period commencing with the execution of this Agreement
and ending at such time that Buyer no longer owns any Securities. For purposes of this Agreement, “Affiliate” means
any person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a person, as such terms are used in and construed under Rule 405 under the 1933 Act.

 

4.
Governing Law; Miscellaneous.

 

4.1.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of Dallas County, Texas or in the federal courts located in Dallas
County, Texas. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. In
the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party
hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in
connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. THE COMPANY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    	 

    	 

    

 

4.2.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but
all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each
party and delivered to the other party.

 

4.3.
Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the
interpretation of, this Agreement.

 

4.4.
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any
law shall not affect the validity or enforceability of any other provision hereof.

 

4.5.
Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of
the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither
the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision
of this Agreement may be waived or amended other than by an instrument in writing signed by the Buyer.

 

4.6.
Notices. Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall
be deemed effectively given on the earliest of:

 

(a)
the date delivered, if delivered by personal delivery as against written receipt therefor or by e-mail to an executive officer,
or by confirmed facsimile,

 

(b)
the fifth Trading Day after deposit, postage prepaid, in the United States Postal Service by registered or certified mail, or

 

(c)
the third Trading Day after mailing by domestic or international express courier, with delivery costs and fees prepaid, in each
case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such
party may designate by ten (10) calendar days’ advance written notice similarly given to each of the other parties hereto):

 

	If to the Company:	The Chron Organization
	 	Attn:
Alex Rodriguez
	 	5851
Legacy Circle, Suite 600
	 	Plano,
TX 75024
	 	 
	If
to the Buyer:	 
	 	 
	 	 
	 	 

 

4.7.
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and assigns. Notwithstanding anything to the contrary herein, the rights, interests or obligations of the Company hereunder may
not be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of the
Buyer, which consent may be withheld at the sole discretion of the Buyer; provided, however, that in the case of a merger,
sale of substantially all of the Company’s assets or other corporate reorganization, the Buyer shall not unreasonably withhold,
condition or delay such consent. This Agreement or any of the severable rights and obligations inuring to the benefit of or to
be performed by Buyer hereunder may be assigned by Buyer to a third party, including its financing sources, in whole or in part,
without the need to obtain the Company’s consent thereto.

 

    	 

    	 

    

 

4.8.
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

4.9.
Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement
shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The
Company agrees to indemnify and hold harmless the Buyer and all its officers, directors, employees, attorneys, and agents for
loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations,
warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement
of expenses as they are incurred.

 

4.10.
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

4.11.
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Buyer by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other
available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining,
preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity
of showing economic loss and without any bond or other security being required.

 

4.12.
Buyer’s Rights and Remedies Cumulative. All rights, remedies, and powers conferred in this Agreement and the Transaction
Documents on the Buyer are cumulative and not exclusive of any other rights or remedies, and shall be in addition to every other
right, power, and remedy that the Buyer may have, whether specifically granted in this Agreement or any other Transaction Document,
or existing at law, in equity, or by statute; and any and all such rights and remedies may be exercised from time to time and
as often and in such order as the Buyer may deem expedient.

 

4.13.
Attorneys’ Fees and Cost of Collection. In the event of any action at law or in equity to enforce or interpret the
terms of this Agreement or any of the other Transaction Documents, the parties agree that the party who is awarded the most money
shall be deemed the prevailing party for all purposes and shall therefore be entitled to an additional award of the full amount
of the attorneys’ fees and expenses paid by such prevailing party in connection with the litigation and/or dispute without
reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall
restrict or impair a court’s power to award fees and expenses for frivolous or bad faith pleading.

 

[Signature
Page Follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above
written.

 

THE
COMPANY:

 

The
Chron Organization, Inc.

 

	By:		 
	 	Alex Rodriguez, CEO	 

 

The
Buyer:

 

	 	 
	Printed Name:	 	 
	Title:	 	 

 

    	 

    	 

    

 

EXHIBIT
A

 

THIS
NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THE SECURITIES UNDER SAID ACT AND LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED.

 

THE
CHRON ORGANIZATION, INC.

 

CONVERTIBLE
PROMISSORY NOTE

 

	$_____________	 	________
    __, 2016

 

Dallas,
Texas

 

FOR
VALUE RECEIVED, the Company promises to pay to the undersigned Investor, or his assigns, in lawful money of the United States
of America the Principal sum of $____________ or such lesser amount as shall equal the outstanding principal amount hereof, together
with interest from the date of this Convertible Promissory Note (the “Note”) or the unpaid Principal at a rate equal
to ten percent (10%) per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. All unpaid
Principal, together with any then unpaid and accrued interest and other amounts payable hereunder, if not converted pursuant to
Section 6 herein, shall be due and payable on the earlier of (i) two years from the date of this Note (the “Maturity Date”)
or (ii) when, upon or after the occurrence of an Event of Default (as defined below), such amounts are declared due and payable
by Investor or made automatically due and payable in accordance with the terms hereof.

 

The
following is a statement of the rights of Investor and the conditions to which this Note is subject, and to which Investor, by
the acceptance of this Note, agrees:

 

1.
Definitions. As used in this Note, the following capitalized terms have the following meanings:

 

(a)
the “Company” includes the corporation initially executing this Note and any Person which shall succeed to
or assume the obligations of the Company under this Note.

 

(b)
“Event of Default” has the meaning given in Section 4 hereof.

 

(c)
“Investor” shall mean the Person specified in the introductory paragraph of this Note or any Person who shall
at the time be the registered holder of this Note.

 

(d)
“Material Adverse Effect” shall mean a material adverse effect on (a) the business, assets, operations, prospects
or financial or other condition of the Company; (b) the ability of the Company to pay or perform the Obligations in accordance
with the terms of this Note and the other Transaction Documents and to avoid an Event of Default, or an event which, with the
giving of notice or the passage of time or both, would constitute an Event of Default, under any Transaction Document; or (c)
the rights and remedies of Investor under this Note, the other Transaction Documents or any related document, instrument or agreement
through no fault of the Company.

 

(e)
“Agreement” has the meaning given in the introductory paragraph hereof.

 

(f)
“Obligations” shall mean and include all loans, advances, debts, liabilities and obligations, howsoever arising,
owed by the Company to Investor of every kind and description (whether or not evidenced by any note or instrument and whether
or not for the payment of money), now existing or hereafter arising under or pursuant to the terms of this Note, the Agreement
and the other Transaction Documents, including, all interest, fees, charges, expenses, attorneys’ fees and costs and accountants’
fees and costs chargeable to and payable by the Company hereunder and thereunder, in each case, whether direct or indirect, absolute
or contingent, due or to become due, and whether or not arising after the commencement of a proceeding under Title 11 of the United
States Code (11 U. S. C. Section 101 et seq.), as amended from time to time (including post-petition interest) and whether or
not allowed or allowable as a claim in any such proceeding.

 

    	 

    	 

    

 

(g)
“Person” shall mean and include an individual, a partnership, a corporation (including a business trust), a
joint stock company, a limited liability company, an unincorporated association, a joint venture or other entity or a governmental
authority.

 

(h)
“Securities Act” shall mean the Securities Act of 1933, as amended.

 

(i)
“Transaction Documents” shall mean this Note, the Securities Purchase Agreement, the Warrant, the Security
Agreement and any other document executed in connection with this Note.

 

2.
Interest. Interest shall be at a rate equal to ten percent (10%) per annum, computed on the basis of the actual number
of days elapsed and a year of 365 days. Accrued interest on this Note shall be payable at maturity.

 

3.
Prepayment. The Company may prepay this Note in whole or in part; provided that any such prepayment will be applied first
to the payment of expenses due under this Note, second to interest accrued on this Note and third, if the amount of prepayment
exceeds the amount of all such expenses and accrued interest, to the payment of principal of this Note.

 

4.
Events of Default. The occurrence of any of the following shall constitute an “Event of Default” under this
Note and the other Transaction Documents:

 

(a)
Failure to Pay. The Company shall fail to pay (i) when due any principal or interest payment on the due date hereunder
or (ii) any other payment or other requirement under the terms of this Note or any other Transaction Document on the date due;
or

 

(b)
Voluntary Bankruptcy or Insolvency Proceedings. The Company shall (i) apply for or consent to the appointment of a receiver,
trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) be unable, or admit in writing
its inability, to pay its debts generally as they mature, (iii) make a general assignment for the benefit of its or any of its
creditors, (iv) be dissolved or liquidated, (v) become insolvent (as such term may be defined or interpreted under any applicable
statute), (vi) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect
to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such
relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding
commenced against it, or (vii) take any action for the purpose of effecting any of the foregoing; or

 

(c)
Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for the appointment of a receiver, trustee, liquidator or
custodian of the Company or of all or a substantial part of the property thereof, or an involuntary case or other proceedings
seeking liquidation, reorganization or other relief with respect to the Company or the debts thereof under any bankruptcy, insolvency
or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding shall not
be dismissed or discharged within 30 days of commencement; or

 

(d)
Material Adverse Effect. One or more conditions exist or events have occurred which could reasonably indicate, or reasonably
result in, a Material Adverse Effect.

 

5.
Rights of Investor upon Default. Upon the occurrence or existence of any Event of Default and at any time thereafter during
the continuance of such Event of Default, Investor may declare all outstanding Obligations payable by the Company hereunder to
be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly
waived, anything contained herein or in the other Transaction Documents to the contrary notwithstanding. Upon the occurrence or
existence of any Event of Default described in Sections 4(b) and 4(c), immediately and without notice, all outstanding Obligations
payable by the Company hereunder shall automatically become immediately due and payable, without presentment, demand, protest
or any other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the other Transaction
Documents to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence or existence of any Event
of Default, Investor may exercise any other right, power or remedy granted to it by the Transaction Documents or otherwise permitted
to it by law, either by suit in equity or by action at law, or both.

 

    	 

    	 

    

 

6.
Conversion.

 

(a)
Conversion. All or a portion of this Note shall be convertible at the option of the Investor into that number of shares
of the Company’s Common Stock as is determined by dividing such Principal amount and accrued interest by seventy percent
(70%) of the VWAP (volume weighted average price) over the prior ten (10) day trading period from date of notice of conversion,
but in no event shall the price be less than $0.02 (adjusted to reflect subsequent stock dividends, stock splits, combinations
or recapitalizations) (the “Conversion Price”). Before Investor shall be entitled to convert this Note into shares
of Common Stock the Investor is entitled to, Investor shall surrender this Note, duly endorsed, at the office of the Company and
shall give written notice to the Company at its principal corporate office, of the election to convert the same pursuant to this
Section, and shall state therein the amount of the unpaid principal amount of this Note to be converted and the name or names
in which the certificate or certificates for shares of Common Stock are to be issued. The Company shall, as soon as practicable
thereafter, issue instructions to its transfer agent to issue to Investor a certificate or certificates for the number of shares
of Common Stock to which Investor shall be entitled upon conversion together with a replacement Note (if any principal amount
is not converted in its entirety) and any other securities and property to which Investor is entitled upon such conversion under
the terms of this Note. The conversion shall be deemed to have been made immediately prior to the close of business on the date
of the surrender of this Note, and the Person or Persons entitled to receive the shares of Common Stock upon such conversion shall
be treated for all purposes as the record Investor or Investors of such shares of Common Stock as of such date.

 

(b)
Fractional Shares; Interest; Effect of Conversion. No fractional shares shall be issued upon conversion of this Note. In
lieu of the Company issuing any fractional shares to Investor upon the conversion of this Note, the Company shall pay to Investor
an amount equal to the product obtained by multiplying the conversion price by the fraction of a share not issued pursuant to
the previous sentence. In addition, the Company shall pay to Investor any interest accrued on the amount to be paid to the Company
pursuant to the previous sentence. Upon conversion of this Note in full and the payment of any amounts specified in this Section
6(a), the Company shall be forever released from all its obligations and liabilities under this Note.

 

7.
Successors and Assigns. Subject to the restrictions on transfer described in Sections 9 and 10 below, the rights and obligations
of the Company and Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of
the parties.

 

8.
Waiver and Amendment. Any provision of this Note may be amended, waived or modified upon the written consent of the Company
and the Investor.

 

9.
Transfer of this Note or Securities Issuable on Conversion Hereof. With respect to any offer, sale or other disposition
of this Note, Investor will give written notice to the Company prior thereto, describing briefly the manner thereof, together
with a written opinion of Investor’s counsel, or other evidence if reasonably satisfactory to the Company, to the effect
that such offer, sale or other distribution may be effected without registration or qualification (under any federal or state
law then in effect). Upon receiving such written notice and reasonably satisfactory opinion, if so requested, or other evidence,
the Company, as promptly as practicable, shall notify Investor that Investor may sell or otherwise dispose of this Note, all in
accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 9
that the opinion of counsel for Investor, or other evidence, is not reasonably satisfactory to the Company, the Company shall
so notify Investor promptly after such determination has been made. Subject to the foregoing transfers of this Note shall be registered
upon registration books maintained for such purpose by or on behalf of the Company as provided in the Note and Warrant Purchase
Agreement. Prior to presentation of this Note for registration of transfer, the Company shall treat the registered holder hereof
as the owner and holder of this Note for the purpose of receiving all payments of principal and interest hereon and for all other
purposes whatsoever, whether or not this Note shall be overdue and the Company shall not be affected by notice to the contrary.

 

    	 

    	 

    

 

10.
Assignment by the Company. Neither this Note nor any of the rights, interests or obligations hereunder may be assigned,
by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of the Investor.

 

11.
Notices. All notices, requests, demands, consents, instructions or other communications required or permitted hereunder
shall in writing and faxed, mailed or delivered to each party at the respective addresses of the parties as set forth in the Agreement,
or at such other address or facsimile number as the Company shall have furnished to Investor in writing. All such notices and
communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one business
day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited
with an overnight courier service of recognized standing or (v) four days after being deposited in the U.S. mail, first class
with postage prepaid.

 

12.
Payment. Payment shall be made in lawful tender of the United States.

 

13.
Governing Law. This Note and all actions arising out of or in connection with this Note shall be governed by and construed
in accordance with the laws of the State of Texas, without regard to the conflicts of law provisions of the State of Texas, or
of any other state.

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Convertible Promissory Note as of the date first set forth above.

 

THE
COMPANY:

 

The
Chron Organization, Inc.

 

	By:	 	 
	 	Alex Rodriguez, CEO	 

 

The
Investor:

 

	 	 
	Printed Name:	 	 
	Title:	 	 

 

    	 

    	 

    

 

EXHIBIT
B

 

THIS
WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED
OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APPLICABLE STATE
SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO The Chron Organization,
Inc. THAT SUCH REGISTRATION IS NOT REQUIRED.

 

THE
CHRON ORGANIZATION, INC.

 

WARRANT
TO PURCHASE SHARES OF COMMON STOCK

 

1.
Issuance. In consideration of good and valuable consideration as set forth in the Securities Purchase Agreement (defined
below), the receipt and sufficiency of which are hereby acknowledged by The Chron Organization, Inc. (OTCPk: CHRO), a Nevada corporation
(the “Company”); _____________________, his/its successors and/or assigns
(the “Holder”), is hereby granted the right to purchase at any time on or after the Issue Date (as defined
below) until the date which is the last calendar day of the month in which the second anniversary of the Issue Date occurs (the
“Expiration Date”), an amount of fully paid and non-assessable shares as determined by the Warrant Calculation
as defined below (the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the
“Common Stock”), as such number of Warrant Shares may be adjusted from time to time pursuant to the terms and
conditions of this Warrant to Purchase Shares of Common Stock (this “Warrant”). This Warrant is being issued
pursuant to the terms of that certain Securities Purchase Agreement dated ________ __, 2016, to which the Company and the Holder
are parties (as the same may be amended from time to time, the “Purchase Agreement”).

 

Unless
otherwise indicated herein, capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase
Agreement.

 

This
Warrant was originally issued to the Holder on ________ __, 2016 (the “Issue Date”).

 

2.
Definitions. As used in this Note, the following capitalized terms have the following meanings:

 

“Affiliate”
shall mean an affiliate as such term is defined in Rule 144 under the Securities Act of 1933, as amended (or a successor rule).

 

“Aggregate
Exercise Price Payable” shall mean the product of multiplying the number of Warrant Shares exercisable by the Exercise
Price.

 

“Closing
Price” shall mean the 4:00 P.M. last sale price of the Common Stock on the Principal Market on the relevant Trading
Day(s), as reported by OTC Markets (or if that service is not then reporting the relevant information regarding the Common Stock,
a comparable reporting service of national reputation selected by the Holder and reasonably acceptable to the Company) for the
relevant date.

 

“Common
Stock Equivalents” shall mean any stock or securities (convertible into or exercisable or exchangeable) for shares of
Common Stock, not including the Company’s employee stock ownership plan.

 

“Exercise
Price” shall mean $0.05 per share.

 

“Market
Price” shall mean the Closing Price for the Common Stock on the Trading Day that is five Trading Days prior to the Exercise
Date or the Issue Date, whichever is greater.

 

    	 

    	 

    

 

“Note”
shall mean that certain Convertible Secured Promissory Note issued by the Company to the Holder pursuant to the Securities Purchase
Agreement, as the same may be amended from time to time, and including any promissory note(s) that replace or are exchanged for
such referenced promissory note.

 

“Trading
Day” means any day during which the principal market on which the Common Stock is traded (the “Principal Market”)
shall be open for business.

 

“Warrant
Calculation” shall mean the calculation to determine the number of Warrants issued hereunder computed using the following
formula:

 

Z
times twenty (20) = Warrants

 

Where
Z = the Amount Invested per the Securities Purchase Agreement converted to a number

(i.e.
$100,000 converted to 100,000 x 20 = 2,000,000 Warrants)

 

3.
Exercise of Warrant. This Warrant is exercisable in whole or in part at any time and from time to time commencing on
the Issue Date and ending on the Expiration Date. Such exercise shall be effectuated by submitting to the Company (either by delivery
to the Company or by email or facsimile transmission) a completed and duly executed Notice of Exercise substantially in the form
attached to this Warrant as Exhibit W-A (the “Notice of Exercise”). The date such Notice of Exercise is either
faxed, emailed or delivered to the Company shall be the “Exercise Date,” provided that, if such exercise represents
the full exercise of the outstanding balance of the Warrant, the Holder shall tender this Warrant to the Company within five (5)
Trading Days thereafter, but only if the Warrant Shares to be delivered pursuant to the Notice of Exercise have been delivered
to the Holder as of such date. The Notice of Exercise shall be executed by the Holder and shall indicate the number of Warrant
Shares (as defined below) to be issued pursuant to such exercise.

 

4.
Mutilation or Loss of Warrant. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction
or mutilation of this Warrant, and (in the case of loss, theft or destruction) receipt of reasonably satisfactory indemnification,
and (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will execute and deliver to the Holder
a new Warrant of like tenor and date and any such lost, stolen, destroyed or mutilated Warrant shall thereupon become void.

 

5.
Rights of the Holder. The Holder shall not, by virtue of this Warrant alone, be entitled to any rights of a stockholder
in the Company, either at law or in equity, and the rights of the Holder with respect to or arising under this Warrant are limited
to those expressed in this Warrant and are not enforceable against the Company except to the extent set forth herein.

 

6.
Call Provision. Notwithstanding anything to the contrary contained in this Warrant, this Warrant is callable (redeemable)
at the Company’s option commencing six (6) months from the Initial Exercise Date, provided the Common Stock trades at a
VWAP of $0.10 or greater for ten (10) consecutive Trading Days on the Trading Market (the “Call Condition”). Commencing
at any time after the date on which the Call Condition is satisfied, the Company shall have the right, upon 20 days’ notice
to the Holder given not later than fifteen (15) Trading Days after the date on which the Call Condition is satisfied (the “Redemption
Notice”), to redeem the number of Warrant Shares specified in the applicable Call Condition at a price of $.001 per Warrant
Share (the “Redemption Price”), on the date set forth in the Redemption Notice, but in no event earlier than 20 days
following the date of the receipt by the Holder of the Redemption Notice (the “Redemption Date”). The Holder may exercise
this Warrant at any time (in whole or in part) prior to the Redemption Date at the Exercise Price. Any portion of this Warrant
that is subject to the applicable Call Condition which is not exercised by the Redemption Date shall no longer be exercisable
and shall be returned to the Company (and, if not so returned, shall automatically be deemed canceled).

 

    	 

    	 

    

 

7.
Certain Adjustments.

 

7.1.
Capital Adjustments. If the Company shall at any time prior to the expiration of this Warrant subdivide the Common Stock,
by split-up or stock split, or otherwise, or combine its Common Stock, or issue additional shares of its Common Stock as a dividend,
the number of Warrant Shares issuable upon the exercise of this Warrant shall forthwith be automatically increased proportionately
in the case of a subdivision, split or stock dividend, or proportionately decreased in the case of a combination. Appropriate
adjustments shall also be made to the Exercise Price, Market Price (in the event of a cashless exercise),, and other applicable
amounts, but the aggregate purchase price payable for the total number of Warrant Shares purchasable under this Warrant (as adjusted)
shall remain the same. Any adjustment under this Section 5.1 shall become effective automatically at the close of business on
the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no
record date is fixed, upon the making of such dividend.

 

7.2.
Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization, or change
in the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section
5.1 above), then the Company shall make appropriate provision so that the Holder shall have the right at any time prior to the
expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and
amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization,
or change by a holder of the same number of shares of Common Stock as were purchasable by the Holder immediately prior to such
reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights
and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or
other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price
per Warrant Share payable hereunder, provided the aggregate purchase price shall remain the same.

 

8.
Certificate as to Adjustments. In each case of any adjustment or readjustment in the shares of Common Stock issuable
on the exercise of this Warrant, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate
designee to compute such adjustment or readjustment in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including
a statement of (a) the consideration received or receivable by the Company for any additional shares of Common Stock issued or
sold or deemed to have been issued or sold, (b) the number of shares of Common Stock outstanding or deemed to be outstanding,
and (c) the Exercise Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately
prior to such adjustment or readjustment and as adjusted or readjusted as provided in this Warrant. The Company will forthwith
mail a copy of each such certificate to the Holder and any Warrant Agent (as defined below) appointed pursuant to Section 8 hereof.
Nothing in this Section 6 shall be deemed to limit any other provision contained herein.

 

9.
Transfer to Comply with the Securities Act. This Warrant, and the Warrant Shares, have not been registered under the
1933 Act. This Warrant, the Warrant Shares and any other security issued or issuable upon exercise of this Warrant may only be
sold, transferred, pledged or hypothecated (other than to an Affiliate) if (a) there exists an effective registration statement
under the 1933 Act relating to such security or (b) the Company has received an opinion of counsel reasonably satisfactory to
the Company that registration is not required under the 1933 Act. Until such time as registration has occurred under the 1933
Act, each certificate for this Warrant, the Warrant Shares and any other security issued or issuable upon exercise of this Warrant
shall contain a legend, in form and substance satisfactory to counsel for the Company, setting forth the restrictions on transfer
contained in this Section 7. Any such transfer shall be accompanied by a transferor assignment substantially in the form attached
to this Warrant as Exhibit W-B (the “Transferor Assignment”), executed by the transferor and the transferee
and submitted to the Company. Upon receipt of the duly executed Transferor Assignment, the Company shall register the transferee
thereon as the new Holder on the books and records of the Company and such transferee shall be deemed a “registered holder”
or “registered assign” for all purposes hereunder, and shall have all the rights of the Holder.

 

10.
Transfer on the Company’s Books. Until this Warrant is transferred on the books of the Company, the Company may
treat the Holder as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

 

    	 

    	 

    

 

11.
Notices. Any notice required or permitted hereunder shall be given in the manner provided in the subsection titled
“Notices” in the Securities Purchase Agreement, the terms of which are incorporated herein by reference.

 

12.
Supplements and Amendments; Whole Agreement. This Warrant may be amended or supplemented only by an instrument
in writing signed by the parties hereto. This Warrant, together with the Purchase Agreement and all the other Transaction Documents,
taken together, contain the full understanding of the parties hereto with respect to the subject matter hereof and thereof and
there are no representations, warranties, agreements or understandings with respect to the subject matter hereof and thereof other
than as expressly contained herein and therein.

 

13.
Governing Law. This Warrant shall be governed by and interpreted in accordance with the laws of the State of Texas,
without giving effect to the principles thereof regarding the conflict of laws. The Company and, by accepting this Warrant, the
Holder, each irrevocably (a) consent to and expressly submit to the exclusive personal jurisdiction of any state or federal court
sitting in Dallas County, Texas in connection with any dispute or proceeding arising out of or relating to this Warrant, (b) agree
that all claims in respect of any such dispute or proceeding may only be heard and determined in any such court, (c) expressly
submit to the venue of any such court for the purposes hereof, and (d) waive any claim of improper venue and any claim or objection
that such courts are an inconvenient forum or any other claim or objection to the bringing of any such proceeding in such jurisdictions
or to any claim that such venue of the suit, action or proceeding is improper. The Company and, by accepting this Warrant, the
Holder, each hereby irrevocably consent to the service of process of any of the aforementioned courts in any such proceeding by
the mailing of copies thereof by reputable overnight courier (e.g., FedEx) or certified mail, postage prepaid, to such party’s
address as provided for herein, such service to become effective ten (10) calendar days after such mailing. THE COMPANY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

14.
Remedies. The remedies at law of the Holder of this Warrant in the event of any default or threatened default by the
Company in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate and, without
limiting any other remedies available to the Holder in the Transaction Documents, law or equity, to the fullest extent permitted
by law, such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or
by an injunction against a violation of any of the terms hereof or otherwise.

 

15.
Counterparts. This Warrant may be executed in any number of counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. Signature
delivered via facsimile or email shall be considered original signatures for purposes hereof.

 

16.
Descriptive Headings. Descriptive headings of the sections of this Warrant are inserted for convenience only and shall
not control or affect the meaning or construction of any of the provisions hereof.

 

17.
Attorney’s Fees. In the event of any litigation or dispute arising from this Warrant, the parties agree that
the party who is awarded the most money shall be deemed the prevailing party for all purposes and shall therefore be entitled
to an additional award of the full amount of the attorneys’ fees and expenses paid by said prevailing party in connection
with the litigation and/or dispute without reduction or apportionment based upon the individual claims or defenses giving rise
to the fees and expenses. Nothing herein shall restrict or impair a court’s power to award fees and expenses for frivolous
or bad faith pleading.

 

18.
Severability. Whenever possible, each provision of this Warrant shall be interpreted in such a manner as to
be effective and valid under applicable law, but if any provision of this Warrant shall be invalid or unenforceable in any jurisdiction,
such provision shall be modified to achieve the objective of the parties to the fullest extent permitted and such invalidity or
unenforceability shall not affect the validity or enforceability of the remainder of this Warrant or the validity or enforceability
of this Warrant in any other jurisdiction.

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed this __ day of ______, 2016.

 

THE
COMPANY:

 

The
Chron Organization, Inc.

 

	By:		 
	 	Alex Rodriguez, CEO	 

 

    	 

    	 

    

 

EXHIBIT
W-A

 

NOTICE
OF EXERCISE OF WARRANT

 

	TO:	The Chron Organization, Inc.
	 	Attn:	 	 
	 	Via Fax to:	 	 
	 	Via Email to:	 	 

 

The
undersigned hereby irrevocably elects to exercise the right, represented by the Warrant to Purchase Shares of Common Stock dated
as of _________, 2016 (the “Warrant”), to purchase shares of the common stock, $0.001 par value (“Common
Stock”), of The Chron Organization, Inc., and tenders herewith payment in accordance with Section 2 of the Warrant,
as follows:

 

_______
CASH: $__________________________ = (Exercise Price x Warrant Shares)

 

_______
Payment is being made by:

 

_____
enclosed check

 

_____
wire transfer

 

_____
other

 

As
contemplated by the Warrant, this Notice of Exercise is being sent by facsimile or email to the fax number and officer indicated
above.

 

If
this Notice of Exercise represents the full exercise of the outstanding balance of the Warrant, the Holder either (1) has previously
surrendered the Warrant to the Company or (2) will surrender (or cause to be surrendered) the Warrant to the Company at the address
indicated above by express courier within five (5) Trading Days after delivery or email or facsimile transmission of this Notice
of Exercise; provided that the Warrant Shares to be delivered pursuant to this Notice of Exercise have been delivered to the Holder
as of such date.

 

To
the extent the Warrant Shares are not able to be delivered to the Holder via the DWAC system, please deliver certificates representing
the Warrant Shares to the Holder via reputable overnight courier after receipt of this Notice of Exercise (by facsimile transmission
or otherwise) to:

 

 

 

 

 

 

 

	Dated:	 	 
	 	 	 
	 	 
	[Name of Holder] 	 
	 	 
	By:	 	 

 

    	 

    	 

    

 

EXHIBIT
W-B

 

FORM
OF TRANSFEROR ENDORSEMENT

(To
be signed only on transfer of the Warrant)

 

For
value received, the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees”
the right represented by the Warrant to Purchase Shares of Common Stock dated as of _________, 2016 (the “Warrant”)
to purchase the percentage and number of shares of common stock, $0.001 par value (“Common Stock”), of The
Chron Organization, Inc.. specified under the headings “Percentage Transferred” and “Number Transferred,”
respectively, opposite the name(s) of such person(s), and appoints each such person attorney to transfer the undersigned’s
respective right on the books of The Chron Organization, Inc. with full power of substitution in the premises.

 

	Transferees	 	Percentage Transferred	 	Number Transferred
	 	 	 	 	 

 

Dated:___________,
______

 

[Transferor
Name must conform to the name of Holder as specified on the face of the Warrant]

 

	 	By:	 
	 	Name:	 

 

Signed
in the presence of:

 

	(Name)	 
	 	 
	ACCEPTED AND AGREED:	 
	 	 
	 	 
	[TRANSFEREE]	 

 

	By:	 	 
	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]